-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Hospital Solutions
-
Business Intelligence and Data Science
-
Commercial Services for Optimal Performance
-
Commercial Engagement Services
-
Commercial Support Solutions
-
Commercial Technologies
-
Real World Evidence
-
Activation Services
-
Clinical Research & Development Solutions
Hospital Solutions
Interested in learning more about how IQVIA can create solutions to help you drive healthcare forward?
OverviewKey Solutions for Hospitals
Business Intelligence and Data Science
As part of the global healthcare community, IQVIA Belgium and its BIDS team (Business Intelligence and Data Science) continuously invest in ways to help life science companies find the next breakthrough in improving human health.
OverviewKey Solutions for Bids
Commercial Services for Optimal Performance
Given the dynamic marketplace, your need to rely on sound information has never been greater. You must make fast decisions without delay. Innovate without undue risk. Execute without faltering.
OverviewKey solutions
Commercial Engagement Services
We can help you get your product to patients quickly. This is done by finding the right candidates to help you in assembling a qualitative team that is trained and equipped with the best tools & applications. With the unique IQVIA approach, we can also make sure you target the right healthcare providers.
OverviewKey solutions
Commercial Support Solutions
IQVIA helps our customers generate real world evidence (RWE) to unlock the value of their investment at every stage of the product life cycle.
OverviewCommercial Technologies
Let yourself be guided and get in direct contact with your key partners in your market. With IQVIA Pharm In Touch, IQVIA Dental In Touch, IQVIA MobiRep and integrated services, you will have even more freedom of movement.
OverviewReal World Evidence
IQVIA helps our customers generate real world evidence (RWE) to unlock the value of their investment at every stage of the product life cycle.
OverviewActivation Services
As the essential partner for pharmacists and pharmaceutical companies we offer effective activation services and marketing tools to meet today's challenges. The Activation Services department of IQVIA is specialised in pharmacy communication and puts its expertise at the service of its partners.
OverviewClinical Research & Development Solutions
Reimagine clinical development by intelligently connecting data, technology and analytics to optimize your trials. The result? Faster decision making, innovation with reduced risk and driving trials without compromise so you can deliver life-changing therapies faster.
OverviewKey solutions
PRODUCTS
-
Pharmaceutical company
Are you a pharmaceuticals ?
IQVIA is a world leader in using data, technology, advanced analytics and human expertise.
OverviewCareers Belgium
Why work at IQVIA Belux? Help create a healthier world—start right here where we offer a diverse selection of opportunities.
Learn moreExplore our Roles
We understand that part of your role involves spending a lot of time on the road, which is why at IQVIA we give you the opportunity to schedule your own agenda.
Learn more
Blog
Thriving in the Complex Landscape of Cardiometabolic Care
Strategies for Navigating Complexity and Seizing Opportunities in Overlapping Therapeutic Markets
May 07, 2025
Introduction
The white paper discusses the renewed focus on cardiometabolic diseases, which include conditions like obesity, heart failure, hypertension, coronary artery disease, chronic kidney disease, dyslipidemia, and diabetes. The biopharmaceutical industry is experiencing a renaissance in this area, driven by the complexity and interdependencies of these diseases.
The Cardiometabolic Opportunity
Cardiometabolic diseases are among the leading causes of mortality and morbidity globally, accounting for over one-third of all global deaths. The overlap between different patient populations with co-morbidities adds complexity to commercializing new products. Innovators need a holistic understanding of patient profiles and unmet needs to guide product development and positioning.
Lessons from Cardiometabolic Commercial Success Stories
The paper identifies three foundational pillars for achieving commercial excellence:
- Deep Market Insights: Knowing your patient population isn’t enough. Innovators must understand how co-morbidities manifest, how patients flow through the system and what different HCPs value. This means using real-world data, integrated care mapping and specialty-specific profiling.
- Aligned Value proposition and customer engagement: Multi-indication products need a clear, coherent narrative that resonates with GPs, endocrinologists, cardiologist, nephrologist and others. Each audience must receive tailored messaging without creating internal confusion or customer fatigue.
- High-Quality Execution: Precision engagement is vital. Leading brands invest in omnichannel strategies, measure performance at the patient level and adapt rapidly. The white paper has a case study on Jardiance which revealed Jardiance’s success in expanding from diabetes to heart failure as a model of focused, cross-specialty engagement.
Organizational Implications for Cardiometabolic Innovators
To succeed, organizations must adopt a portfolio mindset, establish effective governance structures, and leverage advanced analytics capabilities. This includes data-driven planning tools for portfolio-level prioritization and dynamic customer targeting.
Conclusion
Achieving commercial excellence in cardiometabolic innovation requires a strategic approach that integrates deep market insights, aligned value propositions, and high-quality execution. Innovators must navigate the complexities of overlapping patient populations and competitive markets to seize the commercial opportunities in this therapeutic area.